Fri, October 29, 2010
Thu, October 28, 2010
Wed, October 27, 2010
Tue, October 26, 2010
Mon, October 25, 2010
Sun, October 24, 2010
[ Sun, Oct 24th 2010 ] - Market Wire
Alcon Board Elects New Chairman
Sat, October 23, 2010
Fri, October 22, 2010
Thu, October 21, 2010
Wed, October 20, 2010
[ Wed, Oct 20th 2010 ] - Market Wire
STJ, AGAM, BAC, MDT, BSX
Tue, October 19, 2010
Mon, October 18, 2010
Sun, October 17, 2010
Sat, October 16, 2010
Fri, October 15, 2010
[ Fri, Oct 15th 2010 ] - Market Wire
ALGN, FCN, GOOG, SWY, GCI
Thu, October 14, 2010
Wed, October 13, 2010
Tue, October 12, 2010
Mon, October 11, 2010
[ Mon, Oct 11th 2010 ] - Market Wire
30 AM E.T.
[ Mon, Oct 11th 2010 ] - Market Wire
SNY,GENZ,LH,AVB,MU
[ Mon, Oct 11th 2010 ] - Market Wire
ARAY,SI,VAR,TOMO,JMBA

Celldex Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference


//health-fitness.news-articles.net/content/2010/ .. wsmakers-in-the-biotech-industry-conference.html
Published in Health and Fitness on Wednesday, October 20th 2010 at 12:45 GMT by Market Wire   Print publication without navigation


NEEDHAM, Mass.--([ BUSINESS WIRE ])--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Thomas Davis, M.D., Senior Vice President and Chief Medical Officer of Celldex Therapeutics, Inc., will present at the BioCentury NewsMakers in the Biotech Industry Conference onFriday, October 22nd, at 2:00 p.m. EDT in New York City.

A live webcast of the presentation will be available on the aPresentationsa page of the aInvestorsa section of Celldexa™s website at [ http://www.celldextherapeutics.com ] and will be archived for 30 days following the event.

About Celldex Therapeutics, Inc.

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit [ http://www.celldextherapeutics.com ].


Publication Contributing Sources